News Releases

Servier Highlights Commitment to Improving Cancer Outcomes at ASCO 2024

Servier Ranks 1st Across Several Categories in 2023-2024 PatientView U.S. Corporate Reputation Survey

Servier Data Presented at AACR Underscores Unwavering Dedication to Advancing Oncology R&D

Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma

FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma

CStone sells to Servier its exclusive rights to TIBSOVO®in Greater China and Singapore

Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition Through New Data Spotlighting Real-World Treatment Patterns and Clinical Outcomes of Tibsovo® Use at ASH 2023

Servier Expands Base4 Partnership to Advance Neuroscience Drug Development

Nicolas Garnier joins Servier as Chief Patient Officer

Servier Data at ASH 2023 Furthers Leadership in Hard-to-Treat Hematologic Malignancies